INTRACELLULAR PH MEASURED BY 31P MR-SPECTROSCOPY PREDICTS SITE OF PROGRESSION IN RECURRENT GLIOBLASTOMA UNDER ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB

Wenger-Alakmeh K. J.; Pilatus U.; Hattingen E.; Baehr O. R.

首页> 外文期刊>Neuro-Oncology >INTRACELLULAR PH MEASURED BY 31P MR-SPECTROSCOPY PREDICTS SITE OF PROGRESSION IN RECURRENT GLIOBLASTOMA UNDER ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB

【24h】

INTRACELLULAR PH MEASURED BY 31P MR-SPECTROSCOPY PREDICTS SITE OF PROGRESSION IN RECURRENT GLIOBLASTOMA UNDER ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB

机译：抗菌药物联合贝伐单抗治疗复发性胶质母细胞瘤进展中的31P MR波谱预测位点测定细胞内PH

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Neuro-Oncology》 |2016年第4期|iv34-iv34|共1页
作者
Wenger-Alakmeh K. J.; Pilatus U.; Hattingen E.; Baehr O. R.;
展开▼
作者单位

Dr Senckenberg Inst Neurooncol, Frankfurt, Germany;

Brain Imaging Ctr, Inst Neuroradiol, Frankfurt, Germany;

Univ Bonn, Dept Radiol, Div Neuroradiol, Bonn, Germany;

Dr Senckenberg Inst Neurooncol, Frankfurt, Germany;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Intracellular pH measured by 31 31 P‐MR‐spectroscopy might predict site of progression in recurrent glioblastoma under antiangiogenic therapy [J] . Wenger Katharina J., Hattingen Elke, Franz Kea, Journal of magnetic resonance imaging: JMRI . 2017,第4期

机译：通过311111111111111111113测量的细胞内pH可以预测抗血管生成治疗下复发胶质母细胞瘤的进展部位
2. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. [J] . Reardon DA, Desjardins A, Peters K, Journal of neuro-oncology. . 2011,第2期

机译：贝伐珠单抗治疗进展后复发性胶质母细胞瘤的化疗方案的II期临床研究。
3. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. [J] . Reardon DA, Desjardins A, Peters KB, Cancer: A Journal of the American Cancer Society . 2011,第23期

机译：卡铂，伊立替康和贝伐单抗治疗贝伐单抗治疗进展后复发胶质母细胞瘤的2期研究。
4. Applying Quantitative Adiposity Feature Analysis Models to Predict Benefit of Bevacizumab-based Chemotherapy in Ovarian Cancer Patients [C] . Yunzhi Wang, Yuchen Qiu, Theresa Thai, Conference on medical imaging . 2016

机译：应用定量肥胖特征分析模型预测基于贝伐单抗的卵巢癌化疗获益
5. Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma [D] . ADiLiJiang ALiMu 2019

机译：下一代基于测序的转录组预测贝伐单抗联合替莫唑胺在成胶质细胞瘤中的疗效。
6. P07.05 Intracellular pH measured by 31P MR-Spectroscopy predicts site of progression in recurrent glioblastoma under antiangiogenic therapy with bevacizumab [O] . K. J. Wenger-Alakmeh, U. Pilatus, E. Hattingen, 2016

机译：P07.05：通过31P MR光谱法测量的细胞内pH值预测了贝伐单抗抗血管生成治疗后复发性胶质母细胞瘤的进展部位
7. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy [O] . David A. Reardon, Annick Desjardins, Katherine B. Peters, 2011

机译：贝伐单抗治疗后复发胶质母细胞瘤的Carboplatin，Irinotecan和Bevacizumab的第2期研究

INTRACELLULAR PH MEASURED BY 31P MR-SPECTROSCOPY PREDICTS SITE OF PROGRESSION IN RECURRENT GLIOBLASTOMA UNDER ANTIANGIOGENIC THERAPY WITH BEVACIZUMAB

著录项

相似文献

相关主题

期刊订阅